About Us
Corporate History
-
Commenced MEM 3454 Phase 2a CIAS clinical trial
-
Reported positive Phase 2a trial results for MEM 3454 in Alzheimer's Disease
-
Reported Phase 2a trial results of MME 1003 in AD
-
Received $2.0 million milestone from Roche related to the commencement of Phase
1 program for R4996/MEM 63908
-
Secured equity funding from SMRI to support MEM 3454 Phase 2a CIAS trial
-
Reacquired all rights to PDE4 Inhibitor Program from Roche
-
Secured debt financing from Hercules Technology Growth Capital, Inc.
-
Reported Phase 2a trial results for MEM 1003 in bipolar disorder
-
Commenced and completed enrollment for Phase 2a clinical trial of MEM 1003 in
bipolar disorder
-
Earned $960,000 milestone payment from SMRI for Phase 2a bipolar disorder trial
of MEM 1003
-
Received 2007 funding commitment of $2.3 million from Roche for research and
development under the Nicotinic Alpha-7 Alliance
-
Completed $32.2 million financing
-
Achieved $2.0 million milestone from Amgen for preclinical work on PDE10
inhibitors
-
Received 2007 funding commitment of $3.9 million from Amgen for research and
development under the PDE 10 collaboration
-
Received $2.0 million milestone from Roche related to Phase 1 work on MEM 3454
-
Expanded the Nicotinic Alpha-7 Alliance with Roche
-
Reported positive preliminary Phase 1 cognitive data for MEM 3454
-
Entered into partnership with the Stanley Medical Research Institute for
funding support of Phase 2a clinical trial for MEM 1003 in bipolar disorder
-
Commenced dosing in a Phase 2a clinical trial for MEM 1003 in Alzheimer's
disease
-
Entered into collaboration with Amgen for development of PDE10 inhibitors
-
Completed $31 million private placement of common stock and warrants
-
Amended PDE4 Inhibitor collaboration - Memory Pharmaceuticals reacquires rights
to MEM 1414 and MEM 1917, following Roche's decision not to pursue clinical
development of the compounds on its own
-
Recieved $2.0 million milestone payment to maintain its option to obtain an
exclusive license for MEM 3454 from Roche
-
Announced the inclusion of PDE10 Inhibitor Program in our development pipeline
-
Nominated MEM 63908 as drug candidate for the treatment of Alzheimer's disease
-
Commenced a Phase 1 clinical trials for MEM 3454 under Canadian CTA
-
Commenced and completed dosing in safety and tolerability Study for MEM 1003 in
Alzheimer's disease under a U.S. IND
-
Memory Pharmaceuticals selected as a Technology Pioneer of 2005 by World
Economic Forum
-
First Investigational New Drug application filed with the FDA (for MEM 1003)
-
Extended and expanded PDE4 Inhibitor collaboration with Roche
-
Completed Initial Public Offering (Nasdaq: MEMY)
-
Roche commenced Phase 1 clinical trial for MEM 1414
-
Completed Phase 1clinical trial for MEM 1003
-
Roche made equity investment in Memory Pharmaceuticals at a premium
-
Entered into second collaboration with Roche for the development of nicotinic
alpha-7 agonists (Nicotinic Alpha-7 Agonist collaboration)
-
Commenced Phase 1 clinical trial for MEM 1003
-
Entered into first collaboration with Roche for the development of PDE4
inhibitors (PDE4 Inhibitor collaboration)
-
In-licensed MEM 1003, L-type calcium channel modulator
-
Transitioned drug discovery into development
-
Generated proprietary compounds
-
Dr. Eric R. Kandel awarded Nobel Prize in Physiology or Medicine
-
Established laboratory and corporate office in Montvale, New Jersey
-
Filed first patent application
-
Commenced screening of novel chemical entities
-
Aquired license covering Eric Kandel's discoveries
-
Memory Pharmaceuticals Corp. founded by Eric R. Kandel, M.D., Walter Gilbert,
Ph.D., Jonathan Fleming and Axel J. Unterbeck, Ph.D.